Balint G
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary.
Clin Rheumatol. 2002 Feb;21 Suppl 1:S17-8. doi: 10.1007/s100670200032.
Adequate pain control is vital in the treatment of patients with musculoskeletal disease. These diseases are characterised by a number of pain-induced vicious circles, and satisfactory control of pain acts to disrupt these self-perpetuating processes. Consequently, early mobilisation can be achieved in patients with painful osteoporotic vertebral fractures, low back pain and sciatica, for example. In other cases analgesics may act simply to maintain the mobility of patients and in this way preserve their quality of life. When simple analgesics are not sufficient, the use of opioid-type analgesics is justified. Buprenorphine transdermal therapeutic system (TDS) is a novel formulation of a well-tolerated and highly effective drug for satisfactory pain control that can also be used in patients with chronic non-malignant pain (CNMP) due to musculoskeletal diseases. Three case reports are presented to illustrate the effectiveness of buprenorphine TDS in such patients.
充分的疼痛控制在肌肉骨骼疾病患者的治疗中至关重要。这些疾病的特点是存在许多疼痛引起的恶性循环，而对疼痛的满意控制有助于打破这些自我持续的过程。因此，例如，患有疼痛性骨质疏松性椎体骨折、腰痛和坐骨神经痛的患者可以实现早期活动。在其他情况下，镇痛药可能仅仅起到维持患者活动能力的作用，从而以这种方式维持他们的生活质量。当单纯镇痛药不足时，使用阿片类镇痛药是合理的。丁丙诺啡透皮治疗系统（TDS）是一种耐受性良好且高效的药物的新型制剂，用于实现满意的疼痛控制，也可用于患有肌肉骨骼疾病引起的慢性非恶性疼痛（CNMP）的患者。本文介绍了3例病例报告，以说明丁丙诺啡TDS在这类患者中的有效性。
